4/5/2013

The National Institute of Allergy and Infectious Diseases awarded VaxInnate a three-year grant worth $2.2 million to develop a recombinant tetravalent dengue vaccine using its Toll-like receptor (TLR) platform. VaxInnate's TLR technology is intended to better vaccine efficacy and immunogenicity.

Related Summaries